This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.
This paper [
I have no negative comments for this paper, here are some positive comments:
1. I especially find it very impressive that various figures and tables were added to the paper, which shows their thorough work.
Overall, I find this study very impactful especially with the advent of individualized drug therapy and targeted drug recommendations.
2. The results and discussion focus on how recommendations and dosage were changed based on PGx reports and resulted in favorable outcomes for the patients. This shows the utility of PGx in areas where health care professionals are not aware of these interferences or interactions between drug-gene and drug-drug.
3. I am not sure how many clinically relevant genes have changed or updated since April 2016, but this paper lays the groundwork for a more up-to-date gene panel to be used. I would be interested in seeing the outcome with a more up-to-date gene list but that does not necessarily have to be addressed in this paper.
4. This was a very legibly worded paper, and I found no issues with the English or the scientific language that was used.
pharmacogenetic
None declared.